5 Low-Priced Stock Moves to Watch—JYD, SYTA, ENSC, SLXN, and SNOA

April 23, 2025

DENVER, Colo., Apr 23, 2025 (247marketnews.com)- Low-priced stocks with tight floats and compelling catalysts are fueling trader excitement, offering opportunities for quick gains amid volatile markets. Today, 247marketnews.com highlights five NASDAQ stocks to watch: Jayud Global Logistics (JYD), Siyata Mobile (SYTA), Ensysce Biosciences (ENSC), Silexion Therapeutics (SLXN), and Sonoma Pharmaceuticals (SNOA). From short-covering rebounds to transformative patents and strategic partnerships, these tickers are primed for action.

  1. Jayud Global Logistics (NASDAQ:JYD) is rebounding after a massive plunge from $8 on April 1-2. The current uptick, likely driven by short covering, presents scalp opportunities for nimble traders. X chatter suggests retail interest in a quick pop, with resistance at $0.50 and support at $0.30. Approach with caution, as volatility reigns.
  2. Siyata Mobile (NASDAQ:SYTA), with a float of ~4.8 million shares, is trading higher and viewed as significantly undervalued as it advances its $160 million merger with Core Gaming, announced February 26, 2025. The reverse takeover, detailed in its recent SEC Form 20-F, positions SYTA in the $126 billion mobile gaming market, leveraging Core Gaming’s 43 million monthly users and an estimated $80 million in 2024 revenue. Safeguards include a potential special stock dividend ensuring legacy Siyata shareholders retain at least 10% ownership.
  3. Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharma tackling severe pain and opioid abuse, announced a U.S. Patent and Trademark Office Notice of Allowance for its PF9001 OUD treatment, titled “Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof.” With a float of ~5.2 million shares, PF9001 uses TAAP and MPAR technologies to reduce methadone’s cardiac risks, respiratory depression, and overdose potential, offering once-daily dosing.
  4. Silexion Therapeutics (NASDAQ:SLXN), with a float of ~3 million shares, is climbing after announcing a strategic collaboration with Catalent, to develop its siRNA candidate, SIL204, for KRAS-driven cancers. Catalent will handle formulation and manufacturing at its Limoges, France, facility, optimizing SIL204’s systemic and intratumoral delivery for primary tumors and metastases. Preclinical data shows SIL204’s efficacy against KRAS mutations (G12D, G12V, G12R, Q61H, G13D) in pancreatic cancer models.
  5. Sonoma Pharmaceuticals (NASDAQ:SNOA) reported the U.K. MHRA registration of its Microcyn HOCl-based acne toner and serum, enabling a launch across 1,200+ stores of a major U.K. pharmacy chain. SNOA’s low float and revenue potenti trader’s favorite.

Today’s watchlist—JYD’s scalp potential, SYTA’s undervalued merger, ENSC’s OUD patent, SLXN’s cancer therapy collaboration, and SNOA’s U.K. expansion—offers diverse low-priced opportunities.

Please click here to view ValueScope’s Core Gaming valuation report.

To review the SEC Form 20-F filing, please go to https://ir.siyata.net/sec-filings/ or www.sec.gov.

Stay Tuned: Don’t Miss Out

To ensure you don’t miss future announcements, we encourage you to sign up for additional information

For Investor Relation inquiries or to sign up for updates, please click here.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (JYD, SYTA, ENSC, SLXN, SNOA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.